POS is associated with anovulation, hyperandrogenism, and insulin resistance, increasing the risk of cardiovascular diseases and T2DM. Women with POS should undergo complete assessment of lipid profile and glycemic status at the time of diagnosis. Treatment includes, in addition to lifestyle changes, insulin sensitizers, such as metformin or myoinositol, and, for hirsutism and irregular cycles, combined oral contraceptives. Antiobesity agents, such as liraglutide, semaglutide, and GLP-1 agonists and orlistat, can also be indicated for weight control. The gene discussed is GLP1R; the disease is anovulation.